SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Cell-Based and Cell-Free Therapies for Androgenetic Alopecia
Androgenetic alopecia (AGA), commonly known as male or female pattern hair loss, is one of the most prevalent forms of hair loss worldwide. Driven by progressive miniaturization of susceptible hair follicles, AGA affects a substantial proportion of both men and women and can have significant psychological and quality-of-life consequences.
For decades, treatment options have centered primarily on slowing hair loss or stimulating the growth of existing follicles. Minoxidil, finasteride, dutasteride, low-level light therapy, platelet-rich plasma (PRP), and hair transplantation represent the principal approaches currently used in clinical practice.
Yet a new category of therapies is attracting growing attention: regenerative medicine for hair restoration. [Read more…]
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy. [Read more…]
Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform
Non-invasive nose-to-brain delivery system expands treatment options for patients with neurological disorders as an alternative to intrathecal administration.
SAN JOSé DEL CABO, BAJA CALIFORNIA SUR, MEXICO, July 23, 2026 — Longevity Medical Institute® today announced the launch of its Regenerative Neurological Therapy Program, featuring an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. The technology expands the institute’s comprehensive neurological program by offering patients a non-invasive alternative to intrathecal administration for selected neurological conditions.
[Read more…]
Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation
The companies will generate data using Applied StemCell’s induced pluripotent stem cell technologies and Syntax Bio’s Cellgorithm™ platform to support application discovery and development
CHICAGO & MILPITAS, Calif. — Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC’s iPSC and hypoimmune cell lines using Syntax Bio’s proprietary Cellgorithm™ platform to advance stem cell research and therapeutic application discovery and development. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 146
- Next Page »




